Dt&cro KRX:383930KOSDAQ
디티앤씨알오 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days8
Articles tracked6since Sep 11
In Q2 2026, Dt&cro reported revenue of ₩11.3bn, up 12.3% year on year, and an operating loss of ₩6.6bn. Dt&cro (디티앤씨알오) appeared in 0 Korean news articles and 8 DART filings over the past seven days. Coverage peaked on Sep 23 with 6 articles. The most common catalyst was tech & capacity (2).
Filing signals Litigation Screener
Dt&cro quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩11.3bn | +12.3% | −₩6.6bn margin −58.1% | −₩4.1bn |
| Q1 2026 | ₩10.1bn | +0.2% | −₩3.6bn margin −35.4% | −₩13.8bn |
| Q4 2025 derived | ₩15.0bn | +29.2% | ₩621m margin 4.1% | ₩2.7bn |
| Q3 2025 | ₩12.6bn | +19.6% | −₩905m margin −7.2% | −₩2.0bn |
| Q2 2025 | ₩10.1bn | +38.6% | −₩2.0bn margin −19.6% | ₩710m |
| Q1 2025 | ₩10.1bn | +53.6% | −₩3.5bn margin −34.5% | −₩4.3bn |
| Q4 2024 derived | ₩11.6bn | +1448.0% | −₩543m margin −4.7% | ₩9.7bn |
| Q3 2024 | ₩10.5bn | +57.4% | −₩2.0bn margin −19.5% | −₩1.8bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Dt&cro top stories 2 weeks, by number of outlets
- 1
- 2
- 3
Latest Dt&cro news Korean headlines
-
KIMCo재단·디티앤씨알오, 제약·바이오 창업기업 신약개발 지원 맞손
3 more on this story · 3 outlets
- KIMCo재단-디티앤씨알오, 제약·바이오 창업기업 맞춤 지원간호사신문 · Sep 23 10:44
- KIMCo재단-디티앤씨알오, 창업기업 신약개발 지원 협력메드월드뉴스 · Sep 23 12:43
- KIMCo재단-디티앤씨알오, 제약·바이오 창업기업 신약개발 지원 협력한국식품의약신문 · Sep 23 16:04